ARQT
Price
$2.16
Change
-$0.04 (-1.82%)
Updated
Dec 8, 6:59 PM EST
67 days until earnings call
CYTO
Price
$0.41
Change
-$0.10 (-19.61%)
Updated
Dec 8, 6:59 PM EST
Ad is loading...

Analysis and predictions ARQT vs CYTO

Header iconARQT vs CYTO Comparison
Open Charts ARQT vs CYTOBanner chart's image
Arcutis Biotherapeutics
Price$2.16
Change-$0.04 (-1.82%)
Volume$1.05M
CapitalizationN/A
Altamira Therapeutics
Price$0.41
Change-$0.10 (-19.61%)
Volume$5.02M
CapitalizationN/A
View a ticker or compare two or three
ARQT vs CYTO Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
ARQT vs. CYTO commentary
Dec 10, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARQT is a Sell and CYTO is a Hold.

COMPARISON
Comparison
Dec 10, 2023
Stock price -- (ARQT: $2.16 vs. CYTO: $0.41)
Brand notoriety: ARQT and CYTO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARQT: 68% vs. CYTO: 50%
Market capitalization -- ARQT: $184.99M vs. CYTO: $1.76M
ARQT [@Biotechnology] is valued at $184.99M. CYTO’s [@Biotechnology] market capitalization is $1.76M. The market cap for tickers in the [@Biotechnology] industry ranges from $464.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARQT’s FA Score shows that 0 FA rating(s) are green whileCYTO’s FA Score has 1 green FA rating(s).

  • ARQT’s FA Score: 0 green, 5 red.
  • CYTO’s FA Score: 1 green, 4 red.
According to our system of comparison, CYTO is a better buy in the long-term than ARQT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARQT’s TA Score shows that 3 TA indicator(s) are bullish while CYTO’s TA Score has 6 bullish TA indicator(s).

  • ARQT’s TA Score: 3 bullish, 4 bearish.
  • CYTO’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, CYTO is a better buy in the short-term than ARQT.

Price Growth

ARQT (@Biotechnology) experienced а +8.54% price change this week, while CYTO (@Biotechnology) price change was +28.50% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +10161.68%. For the same industry, the average monthly price growth was +8.48%, and the average quarterly price growth was +27.10%.

Reported Earning Dates

ARQT is expected to report earnings on Feb 14, 2024.

CYTO is expected to report earnings on Nov 17, 2022.

Industries' Descriptions

@Biotechnology (+10161.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for ARQT with price predictions.
OPEN
A.I.dvisor published
a Summary for CYTO with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
ARQT($185M) has a higher market cap than CYTO($1.76M). ARQT YTD gains are higher at: -85.405 vs. CYTO (-91.548). CYTO has higher annual earnings (EBITDA): -22.48M vs. ARQT (-234.44M). ARQT has more cash in the bank: 227M vs. CYTO (49.6K). CYTO has less debt than ARQT: CYTO (3.47M) vs ARQT (205M). ARQT has higher revenues than CYTO: ARQT (49M) vs CYTO (120K).
ARQTCYTOARQT / CYTO
Capitalization185M1.76M10,505%
EBITDA-234.44M-22.48M1,043%
Gain YTD-85.405-91.54893%
P/E RatioN/AN/A-
Revenue49M120K40,833%
Total Cash227M49.6K457,661%
Total Debt205M3.47M5,913%
FUNDAMENTALS RATINGS
CYTO: Fundamental Ratings
CYTO
OUTLOOK RATING
1..100
26
VALUATION
overvalued / fair valued / undervalued
1..100
20
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
34
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
17

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ARQTCYTO
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 4 days ago
83%
Declines
ODDS (%)
Bearish Trend 10 days ago
90%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PFPWX48.850.13
+0.27%
Parnassus Value Equity Institutional
SUICX46.730.09
+0.19%
DWS CROCI International C
GGFRX11.46N/A
N/A
Nationwide BNY Mellon Dyn US Core R
FAPHX10.89N/A
N/A
Fidelity® Healthy Future
FCEEX9.18-0.03
-0.33%
Franklin Emerging Market Core Equity Adv

ARQT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARQT has been loosely correlated with MDGL. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ARQT jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARQT
1D Price
Change %
ARQT100%
-1.82%
MDGL - ARQT
46%
Loosely correlated
-11.58%
ORMP - ARQT
40%
Loosely correlated
-0.44%
GBIO - ARQT
38%
Loosely correlated
-3.45%
IMAB - ARQT
38%
Loosely correlated
-3.85%
BEAM - ARQT
37%
Loosely correlated
-8.17%
More